Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 1/20 | 0.50 |
| ▸ | STAT3 | P40763 | 1/20 | 0.48 |
| ▸ | CYP1A1 | P04798 | 8/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 8/20 | 0.47 |
| ▸ | CYP1B1 | Q16678 | 8/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | APP | P05067 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6167179 | 1.00 | PDE4D (0.50) | PDE4DSTAT3CYP1A1CYP1A2CYP1B1 | |
| SCHEMBL6168708 | 0.80 | CYP1A1 (0.56) | STAT3CYP1A1CYP1A2CYP1B1CYP3A4 | |
| SCHEMBL6168714 | 0.80 | CYP1A1 (0.56) | STAT3CYP1A1CYP1A2CYP1B1CYP3A4 | |
| SCHEMBL3218730 | 0.75 | APP (0.74) | STAT3CYP1A2CYP3A4CYP2D6NFKB1 | |
| SCHEMBL3218712 | 0.75 | APP (0.74) | STAT3CYP1A2CYP3A4CYP2D6NFKB1 | |
| SCHEMBL6166941 | 0.72 | CYP1A1 (0.53) | CYP1A1CYP1A2CYP1B1CYP3A4CYP2D6 | |
| SCHEMBL6166690 | 0.72 | CYP1A1 (0.58) | CYP1A1CYP1A2CYP1B1CYP3A4CYP2D6 | |
| SCHEMBL6167464 | 0.72 | CYP1A1 (0.67) | CYP1A1CYP1A2CYP1B1CYP3A4CYP2D6 | |
| SCHEMBL6166697 | 0.72 | CYP1A1 (0.58) | CYP1A1CYP1A2CYP1B1CYP3A4CYP2D6 | |
| SCHEMBL6166947 | 0.72 | CYP1A1 (0.53) | CYP1A1CYP1A2CYP1B1CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050187264-A1 | Phosphodiesterase iv inhibitor containing pyridylacrylamide derivative | TSUMURA & CO. (JP) | 2005-08-25 | — | — | US | disclosed |
| EP-1495757-A1 | PHOSPHODIESTERASE IV INHIBITOR CONTAINING PYRIDYLACRYLAMIDE DERIVATIVE | TSUMURA & CO. (JP) | 2005-01-12 | — | — | EP | disclosed |
| US-6313153-B1 | ADMINISTERING PYRIDYLACRYLAMIDE COMPOUND FOR THERAPY OF NEPHRITIS | TSUMURA & CO. (JP) | 2001-11-06 | — | — | US | disclosed |
| EP-1000935-A1 | PYRIDYLACRYLAMIDE DERIVATIVES AND NEPHRITIS REMEDIES AND TGF-$g(b) INHIBITORS CONTAINING THE SAME | TSUMURA & CO. (JP) | 2000-05-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187264-A1 | Phosphodiesterase iv inhibitor containing pyridylacrylamide derivative | PDE3B, PDE3A, PDE2A | PDE4D 13/4885STAT3 3046/4885CYP1A1 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.